News
Savara Reports First Quarter 2022 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2022 and provided a
Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ)
Chemed Corporation to Present at the 2022 RBC Capital Markets Global Healthcare Conference
Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022, at approximately 8:00 a.m. (ET)
QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has signed agreements to acquire a 96% majority ownership stake in BLIRT SA (Polish Stock Exchange: BLR), a
QIAGEN erwirbt Mehrheitsanteil an Enzym-Hersteller BLIRT S.A.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass das Unternehmen Vereinbarungen über den Erwerb einer Mehrheitsbeteiligung von 96 % an dem Unternehmen BLIRT S.A
Geratherm Medical AG: Voluntary delisting offer by JotWe GmbH published
QIAGEN Proposes Expansion of Supervisory Board
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the proposal of Dr. Eva Pisa, a leader in health diagnostics and biotechnology who has extensive experience from start-ups to
QIAGEN schlägt Erweiterung des Aufsichtsrats vor
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass Dr. Eva Pisa als neues Aufsichtsratsmitglied vorgeschlagen wurde. Als Führungsperson in der Gesundheitsdiagnostik und
DGAP-News: Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Alpha Radioisotopes
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website
Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Cervical Cancer
Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx, Code SK006, is now EU CE-IVD–marked for use in cervical cancer. PD-L1 IHC 22C3 pharmDx can be used as an aid in
Transgene: Q1 2022 Financial Position and Business Update
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update for the
Humana Specialty Pharmacy Receives Prestigious National Patient Choice Award for Fifth Consecutive Year
Humana Specialty Pharmacy has won the MMIT Specialty Pharmacy Patient Choice Award in the PBM/Payer category for the fifth year in a row. The award recognizes best-in-class customer satisfaction
Dexcom Announces Upcoming Conference Presentations
DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the following upcoming investor
Pfizer to Acquire Biohaven Pharmaceuticals
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire
Aurinia Reports First Quarter 2022 Financial and Operational Results
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the first quarter ended March 31, 2022. Amounts, unless specified otherwise, are
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 31, 2022
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
DGAP-News: Formycon AG and ATHOS KG announce closing of transaction to acquire biosimilar assets FYB201 and FYB202 as well as Bioeq GmbH
DGAP-Adhoc: Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure
Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ)
Relief Therapeutics to Participate in Industry and Investor Conferences in May
Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) announces a change to the dial-in number(s) for the upcoming first quarter financial and operational results announcement on
IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022
IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and